The mitogenic extracellular kinase 1/2 (MEK1/2) inhibitor, PD0325901, has potent activity in a number of cancer cell types in vitro. In SKMEL-28 human melanoma cells (BRAF mutant), the drug rapidly decreased phosphorylated extracellular signal-regulated kinase 1/2, cyclin D1, and thymidine kinase 1 protein levels. We investigated if 3 ¶-deoxy-3 ¶-[ 18
Introduction
The mitogen-activated protein kinase (MAPK) pathway involving RAS, RAF, mitogenic extracellular kinase (MEK1/2), and extracellular signal-regulated kinase (ERK) regulate cell proliferation, survival, and differentiation in response to extracellular signals. The pathway is activated in several cancers with overall mutation rates of f15% to 30% for RAS (1) and f7% for BRAF (2) . In human melanoma, BRAF mutations occur in f66% of cases (2) , with the most common mutation being a glutamic acid for valine substitution at position 600 (V600E). This substitution, by mimicking phosphorylation of the activation segment, activates BRAF f500-fold and stimulates constitutive MAPK activity (3) . In colorectal cancer, K-RAS mutations occur in f27% of cases (4) . The MAPK pathway is therefore a key target for therapeutic intervention. MEK1/2 has no reported oncogenic properties but serves as a central axis for this pathway.
A number of drugs, including CI-1040, PD0325901, and AZD6244 have been developed to target MEK1/2 (5 -9). Activating mutations in BRAF and RAS have been shown to sensitize cells to these MEK1/2 inhibitors (6, 9) , but clinical response is not limited to tumors harboring such mutations (5) . Furthermore, all these inhibitors have been shown to reduce levels of phosphorylated ERK1/2 (pERK1/2) in cells in vitro or in tumor biopsies (5 -9) , although the best clinical response observed has been stable disease (5, 7, 8) . These findings indicate that reduction in pERK1/2 does not necessarily predict growth inhibition. Cell proliferation has been proposed as a useful biomarker of MEK1/2 inhibition (10). Clearly, assessment of cell proliferation by imaging will be more desirable than multiple biopsy methods. In the present study, we examined the relationship between imaging variables derived from 3 ¶-deoxy-3 ¶- [ 18 F]fluorothymidine-positron emission tomography ([ 18 F]FLT-PET) and cognate biochemical effects of the MEK1/2 inhibitor PD0325901 (9) . [ 18 F]FLT-PET measures thymidine kinase 1 (TK1) activity in vivo (11, 12) . A decrease in the activities of G 1 phase cyclins and retinoblastoma hypophosphorylation regulate TK1 mRNA and protein, leading to decreases in [ 18 F]FLT uptake (13) . Efficacious doses of cytotoxic drugs and gene therapies also induce reductions in tumor [ 18 F]FLT uptake (14, 15 (16) . However, dynamic imaging was not done in that study; therefore, the value of different imaging variables and their relationship(s) to proliferation signals were not established. Prior to in vivo studies with PD0325901, we established the time course of drug effect in a sensitive cell line (SKMEL-28) in vitro. The potential of different [
18 F]FLT-PET variables as downstream pharmacodynamic imaging end points of growth inhibition following MEK1/2 inhibition was then assessed in two human tumor xenograft models-SKMEL-28 melanoma and HCT116 colorectal cancer.
Materials and Methods
Radiopharmaceuticals and Drug [ 18 F]FLT was synthesized by radiofluorination of the 3-Nboc-5 ¶-O-dimethoxytrityl-3 ¶-O-nosyl-thymidine precursor using a GE TracerLab MX synthesis module (GE Healthcare UK Limited) based on a previously described method (17) . All samples had >98% radiochemical purity as determined by high-performance liquid chromatography with radiochemical detection, and the specific radioactivity was 120 to 150 GBq/Amol at the end of the synthesis. Cell Culture and Treatment SKMEL-28 and HCT116 cells were cultured in RPMI 1640 growth medium containing 10% (v/v) fetal bovine serum, 2 mmol/L of L-glutamine, 100 units/mL of penicillin, and 100 g/mL of streptomycin and grown in a 5% CO 2 incubator at 37jC. Cells in exponential growth were used for subsequent studies. To examine the effect of PD0325901 in vitro on SKMEL-28 cells, the growth medium was replaced with medium containing 1 Amol/L of PD0325901 or DMSO (the final concentration of DMSO in both cases was 0.1%). The plates were then incubated for 0.5, 2, 4, 24, or 48 hours and harvested.
Protein Analysis The levels of pERK1/2, total ERK1/2, cyclin D1, TK1, pAKT, total AKT, cleaved caspase-3 (Asp 175 ), and h-actin (loading control) protein were determined by Western blot analysis. In addition, Western blot analyses were also done on excised frozen tumor material. For this, SKMEL-28 and HCT116 tumors (after imaging studies) were snap-frozen in liquid nitrogen and stored at À80jC until analysis. The tumors were pulverized in liquid nitrogen and homogenized in 100 AL of ice-cold triple detergent buffer [50 mmol/L Tris-HCl (pH 8.0), 150 nmol/L NaCl, 0.02% sodium azide, 0.1% SDS, 1% NP40, 0.5% sodium deoxycholate, and 10 AL/mL protease inhibitor mixture]. Lysates were clarified by centrifugation (15,000 Â g for 10 min at 4jC) and the supernatants were analyzed for total protein content using a commercial bicinchoninic acid protein assay kit (Perbio Science). Aliquots of the supernatant (containing 30 Ag of protein) were assayed as previously reported (13) .
The primary antibodies used in this study included the following: rabbit polyclonal anti-phosphorylated p44/42 MAPK (Thr 202 /Tyr 204 ) antibody (1:1,000), rabbit polyclonal anti-total p44/42 MAPK antibody (1:1,000 dilution), rabbit polyclonal anti -cyclin D1 antibody (1:1,000), mouse biotinylated monoclonal anti-TK1 (no. 1-8-5:4-1D11, 1:20,000 dilution; Svanova Biotech), rabbit polyclonal antiphosphorylated pAKT and rabbit polyclonal anti-total AKT (Cell Signaling Technology), cleaved caspase-3 (Asp 175 ), and mouse polyclonal anti -h-actin (1:2,000; Santa Cruz Biotechnology). The membranes were processed and bands were quantified as previously reported (13) . Four tumor samples were analyzed from each of the control and treatment groups.
Determination of mRNA Levels by Quantitative Realtime PCR
The effect of 1 Amol/L of PD0325901 on the transcription of a number of candidate genes was assessed in SKMEL-28 cells. Cells were washed and RNA from the cells was extracted with Trizol (Invitrogen Life Technologies) as per the manufacturer's instructions with a slight modification in that the aqueous phase was cleaned up with chloroform/isoamyl alcohol mixture (24:1).
The cDNA generated was used as a template in real-time PCR reactions with a SYBR-Green PCR master mix (Applied Biosystems). All amplification reactions were done in triplicate using 96-well optical reaction plates (MicroAmp, Applied Biosystems) on an Applied Biosystem 7500 Fast System. The results were then normalized to the housekeeping gene HPRT and expressed as a ratio. The primers were designed from the literature or from the GenBank Ensembl sequence. The sequences were assessed for species-specificity by a BLAST search. 5 Where possible, primers were designed to cover putative introns. Dissociation curves were done after each PCR run to ensure that a single PCR product had been amplified. The products were also analyzed by gel electrophoresis and sequencing on a primer pair to ensure that the correct gene fragment was amplified. Levels of the PCR-amplified HPRT were found to be constant for all the treatment groups, indicating suitability for use as a control (data not shown). The PCR primers (Supplementary Table S1 ) 6 were synthesized by Sigma-Genosys.
Determination of ATP Levels Because [ 18 F]FLT uptake is dependent not just on TK1, but also ATP (11), we examined the effect of PD0325901 on ATP in tumor samples. ATP levels were determined by a bioluminescence assay (ENLITEN ATP assay system; Promega) as previously reported (13 (18) . We used two xenograft models to assess the biological activity of PD0325901, i.e., human melanoma SKMEL-28 and human colon carcinoma HCT116 xenografts. Six-to 8-week-old BALB/c nu/nu mice were obtained from Harlan United Kingdom, Ltd., and tumors were induced by s.c. inoculation of 5 Â 10 6 SKMEL-28 cells (BRAF mutant) or HCT116 cells (K-RAS mutant) on the back of the mice. SKMEL-28 cells were prepared as a suspension in 25% of growth medium in basement membrane matrix (BD Matrigel; BD Bioscience); HCT116 cells were prepared in PBS. Tumor dimensions were measured continuously using a caliper and tumor volumes were calculated by the equation: volume = (p/6) Â a Â b Â c, where a, b, and c represent three orthogonal axes of the tumor. Mice were used when their tumors reached f100 mm 3 . Size-matched tumor-bearing mice were randomized to receive 25 mg/kg (0.005 mL/g mouse) of PD0325901 or vehicle (0.5% hydroxypropyl methylcellulose plus 0.2% Tween 80) daily by oral gavage. [ 18 F]FLT-PET scanning was done at f25 hours after commencing treatment (i.e., after two doses with the second dose given 1 hour before scanning) or after 10 daily treatments (again with the last dose given 1 hour before scanning). After imaging, one part of the tumor was snap-frozen in liquid nitrogen and stored at À80jC; the other part was fixed in formal saline.
PET Imaging Studies Dynamic [ 18 F]FLT-PET studies were carried out on a dedicated small animal PET scanner, quad-HIDAC (Oxford Positron Systems). The features of this instrument have been previously described (19) . Scanning was done using a previously reported protocol (13) . Dynamic scans were acquired in list-mode format over a 60-min period.
Image Analysis and Quantification Cumulative images comprising of 30 to 60 min of the dynamic data were used for visualization of radiotracer uptake and to draw regions of interest. Regions of interest were defined on five tumor and five heart-slices (each 0.5 mm in thickness). Dynamic data from these slices were averaged for each tissue and at each of the 19 time points to obtain time versus radioactivity curves for these tissues. Tumor radioactivity was corrected for physical decay and normalized to that of heart to obtain a standardized uptake value (NUV). The NUV at 60 min postinjection (NUV 60 ) was used for comparisons; to improve signal-to-noise ratio, NUV max was also calculated in a similar manner as NUV 60 except that maximal voxel radioactivities for each tumors' region of interest were used. The area under the NUV curve (AUC) was calculated as the integral of NUV from 0 to 60 min. The fractional retention of tracer (FRT) at 60 min relative to that at 1.5 min was also calculated (13) .
Immunohistochemical Analysis of Proliferation PD0325901-and vehicle-treated tumors (n = 4 each) were excised after imaging, fixed in formalin, embedded in paraffin, and cut into 5.0-Am sections. The degree of tumor proliferation was assessed in tumor sections as previously described (13) . For each tumor section, the total number of Ki67-positive brown-stained cells and hematoxylin-stained cells were counted in 16 randomly selected fields of view using an Olympus BX51 microscope (Olympus UK, Ltd.) at Â400 magnification. The Ki67 labeling index (LI Ki67 ) was calculated using the equation LI Ki67 = [Ki67-positive cells / (total cells)] Â 100%.
Double-Labeled Immunofluorescence
Deparaffinized sections were fixed in 3% to 4% paraformaldehyde in PBS (pH 7.4) for 15 min at room temperature and permeabilized for 20 min with PBS containing 0.25% Triton X-100 at room temperature, and then washed thrice with PBS for 5 min. After washing, the sections were blocked with 1% bovine serum albumin in PBS containing 0.25% Triton X-100 for 30 min at room temperature. Subsequently, they were incubated with a mixture of pERK1/2 antibodies (1:100; Cell Signaling) and Ki67 antibodies (1:100; Dako) diluted in 1% bovine serum albumin in PBS containing 0.25% Triton X-100 for 16 h at 4jC. After washing (five times) with PBS, the sections were incubated for 1 hour at room temperature with a mixture of Alexa Fluor 488 -conjugated goat anti-rabbit antibodies (Invitrogen) diluted 1:400 and Alexa Fluor 594 -conjugated goat anti-mouse antibodies (Invitrogen) diluted 1:400 in 1% bovine serum albumin. The sections were then washed five times with PBS and mounted with gel mount containing 4 ¶,6-diamidino-2-phenylindole (Invitrogen). Specimens were examined for fluorescence with an Olympus BX51 microscope (Olympus); the results were compared with H&E staining.
Statistical Analysis Data were expressed as mean F SE. Statistical analyses were done using the software GraphPad Prism, version 3.03 (GraphPad). Group comparisons were assessed using the nonparametric Mann-Whitney test. Correlations between tumor radiotracer levels and LI Ki67 were determined (Pearson correlation). Two-tailed P V 0.05 were considered significant.
Results

Suppression of ERK1/2 Phosphorylation by PD0325901 in SKMEL-28 cells
The phosphorylation of ERK1/2 protein (44/42 kDa) was detected by Western blotting. A time-dependent reduction in pERK1/2 was induced by 1 Amol/L of PD0325901 (Fig. 1A) . Maximum and significant reduction of pERK1/2 was observed at 4 hours compared with vehicle control (P = 0.03) after treating cells with PD0325901, and there was partial recovery of the protein at 24 and 48 hours after treatment (P = 0.05). The observed change in pERK1/2 expression was not accompanied by changes in total ERK1/2 expression, indicating that the reduction in ERK1/2 phosphorylation by PD0325901 was not due to a depletion of the protein.
PD03259 01 Inhibits Cyclin D1 and TK1 Protein Expression, and Induces the Cleavage of Caspase-3 in SKMEL-28 Cells
In most cell types, sustained activation of MAPK signaling pathway leads to activation of the cyclin Dcdk4 complex to modulate cell proliferation (9, 20, 21) . PD0325901 (1 Amol/L) reduced cyclin D1 protein expression (Fig. 1B) at 24 and 48 hours after treatment compared with vehicle control (P = 0.03). Compared with pERK1/2 (Fig. 1B) , the recovery of cyclin D1 was slower. Like cyclin D1 protein, TK1 protein levels decreased with PD0325901 treatment in a time-dependent manner (Fig. 1C) ; the decrease in TK1 expression following drug treatment was also slower than those for pERK1/2, with maximum reduction at 48 hours posttreatment (P = 0.03). The drug caused a small but significant induction of caspase-3 (Fig. 1D) . Lastly, as a negative control, we examined the effect of PD0325901 on pAKT levels. No consistent time-related alterations in pAKT levels were observed (Fig. 1E) at the drug concentration used (1 Amol/L).
P0325901InhibitsTK1and Cyclin D1mRNA Expression The mRNA levels of TK1, cyclin D1, and ELK in SKMEL-28 cells were all significantly down-regulated within hours following treatment with 1 Amol/L of PD0325901 compared with vehicle control ( Fig. 2A -C) . Significant inhibition of cyclin D1 and TK1 mRNA was detectable at the earliest time point (4 hours; P = 0.001 and 0.03, respectively) and persisted for the duration of the study (48 hours). The nuclear transcription factor ELK, which is a direct downstream target of pERK1/2 (22, 23) was also down-regulated at 4 hours in response to PD0325901. The recovery kinetics of ELK were, however, more rapid than those for cyclin D1 and TK1. Of note, PD0325901 also induced a significant G 1 arrest at the lowest dose concentration studied (0.01 Amol/L): 81.6 F 0.8% of cells were in G 1 phase compared with 56.8 F 4.4% for vehicle control (P = 0.03; Supplementary Fig. S1 ). 6 Effect of PD0325901on SKMEL-28 and HCT116 Tumor Growth For both tumor types, tumor volumes were not significantly reduced at day 1 following PD0325901 (25 mg/kg) treatment (Fig. 3A) . In SKMEL-28, tumor volume changed from 168.0 F 38. 5 Fig. 3B . Qualitative reductions in radiotracer localization were observed in the tumors of PD0325901-treated mice. Whereas NUV increased over time in vehicletreated tumors, PD0325901 induced significant reductions in [ 18 F]FLT uptake compared with vehicle treatment (Fig. 3C and D) . Summary data are presented in Table 1 and show that although the NUV 60 , NUV max , AUC, and FRT were unchanged in the vehicle control groups, all the variables were significantly lower in the PD0325901-treated groups compared with corresponding vehicle-treated groups. FRT in HCT116 tumor decreased but the decrease was not statistically significant.
In vivo Activity of PD0325901 is Associated with Reductions in Ki67 Labeling and TK1 Protein Levels in SKMEL-28 and HCT116 Xenografts
Significant changes in LI Ki67 were seen after 1 and 10 days of drug treatment in SKMEL-28 xenografts (P = 0.03 for both; Fig. 4A and B) . Similarly, LI Ki67 was lower in HCT116 tumors after 10 days of drug treatment (P = 0.05; Fig. 4C ). In this tumor, changes in LI Ki67 at day 1 were not statistically significant. All tumor data (SKMEL-28 and HCT116) were combined for the assessment of the degree of association between tumor [
18 F]FLT kinetic variables and cell proliferation. The correlation coefficient (r ) between LI Ki67 and NUV 60 was 0.630 (P = 0.001), and that for LI Ki67 versus FRT was 0.596 (P = 0.003); LI Ki67 versus AUC was also significant (r = 0.647; P = 0.002). There was also a significant correlation between [ 18 F]FLT kinetic variables and tumor TK1 expression: r was 0.518 (P = 0.002), 0.423 (P = 0.015), and 0.480 (P = 0.005) for NUV 60 , AUC, and FRT, respectively. Significant reductions in pERK1/2, cyclin D1, and TK1 protein levels were observed after drug treatment in vivo compared with vehicle controls (Supplementary Table S2 ). ATP levels were also significantly lower after 1 and 10 days of drug treatment compared with controls (Supplementary  Table S2 ). 6 
Double-Immunofluorescence Detection of pERK1/2 and Ki67 in SKMEL-28 Tumors
The coexpression of Ki67 and pERK1/2 in SKMEL-28 tumor sections is shown in Fig. 5 . Whereas Ki67-positivity (red) was confined to the nucleus pERK1/2-positivity (green) was both nuclear and cytoplasmic. Coexpression of pERK1/2-positive cells and Ki67-positive cells was indicated by the yellow fluorescence. In vehicle-treated tumors, almost all the pERK1/2-positive cells were also Ki67-positive (Fig. 5A) . The coexpression of pERK1/2 and Ki67 was detectable after 1 day of PD0325901 treatment but the total number of (yellow) cells within the tumor mass had decreased (Fig. 5B) . At 10 days after PD0325901 treatment, Ki67 nuclear staining was barely detectable. In contrast, there were pockets of cells with pERK1/2 cytoplasmic staining; no pERK1/2 nuclear staining was detectable (Fig. 5C) .
Discussion
We have shown that the reduction in cell proliferation induced by PD0325901 is detectable by [ 18 F]FLT-PET variables NUV 60 , NUV max , AUC, and FRT. The MAPK signal transduction pathway is an attractive target for therapeutic intervention because several cancers harbor amplifications and mutations of genes within the pathway leading to constitutive activation of downstream effectors. In preclinical models, MEK1/2 inhibitors showed activity in tumors harboring mutations in BRAF or RAS (6, 9). In recent phase I and II clinical trials of these inhibitors, stable disease was observed as the best clinical outcome despite significant reductions in pERK1/2 levels (5, 7, 8). Smalley and coworkers (10) (16) .
[ 18 F]FLT uptake into tumors is a function of the levels of the TK1 enzyme and of the cofactor ATP (11, 12) . Studies in xenograft models (13 -15, 19) and in human tumors (24, 25) have shown strong correlations between [
18 F]FLT uptake and LI Ki67 . In vitro studies in SKMEL-28 cells showed that mRNA and protein levels of TK1 were rapidly decreased after MEK1/2 inhibition by PD0325901 (Figs. 1 and 2 ). These findings, together with the strong G 1 arrest in treated cells, suggested that [
18 F]FLT might be a useful biomarker for imaging MEK1/2 inhibition by PD0325901. The time course studies after single drug dosing indicated that recovery of pERK1/2 and ELK was more rapid than that for the protein/mRNA for cyclin D1 and TK1. These findings indicate that a TK1-based imaging probe will not measure MEK1/2 activity directly but rather downstream effects of MEK1/2 inhibition, the kinetics of which may be somewhat different from direct target activity.
Treatment of SKMEL-28 and HCT116 tumors led to reductions in [ 18 F]FLT uptake in drug-treated mice compared with vehicle controls. In contrast with previous reports suggesting that cells with K-RAS mutation are unresponsive to PD0325901 (9), we saw [ 18 F]FLT responses in the HCT116 tumor model. In these imaging studies, baseline radiotracer uptake should be assumed to be similar to that in day 1 vehicle-treated mice. In previous [
18 F]FLT imaging studies in RIF-1 (14) and IGROV-1 (15), we found no differences between radiotracer uptake/biochemical variables in size-matched untreated tumors versus tumors treated with vehicle for 1 day, and therefore, as with recent studies, we compared day 1 vehicle-treated to day 1 drug-treated groups (13, 26) . The lower [
18 F]FLT uptake in drug-treated compared with vehicle-treated tumors at day 1, therefore, supports the assertion that [ 18 F]FLT-PET imaging can be used to measure early changes in proliferation following PD0325901 treatment. Of interest, where drug effects on proliferation are delayed, we see no early changes in tumor [ 18 F]FLT uptake, as shown in a recent study (26) . The study design reported here is different from one that will be used clinically, i.e., pretreatment scans followed by posttreatment scans in the same patient, but is useful in that it permits direct comparison of the imaging end point to tumor biochemistry in individual animal tumors.
In (13 -15, 19) and humans (27) , and supports the notion that changes in proliferation are more sensitive and precede tumor size changes. The groupaveraged PET kinetic variables may, however, have been influenced by spatial differences in radiotracer uptake, which could have introduced errors in averaging of [ 18 F]FLT within regions of interest. For instance, although the group-averaged NUV 60 was unchanged between days 1 and 10 for drug-treated SKMEL-28, LI Ki67 decreased. The reduction of NUV max was more consistent with changes in LI Ki67 than in NUV 60 , presumably because of the lower signal-to-noise characteristics of the former. The reduction in PET variables was consistent with changes in TK1 enzyme and ATP levels in vivo. A more detailed study to link the effect of PD0325901 on pERK1/2 to changes in Ki67 showed a time-dependent reduction in both pERK1/2 and Ki67 expression by PD0325901. The presence of Ki67-negative pERK1/2 (cytoplasmic) -positive cells in tumors treated with PD0325901 for 10 days is consistent with the need for pERK1/2 to translocate to the nucleus in order to affect transcription (20 -23) . Analysis of tumor material by Western blotting does not discriminate cytoplasmic from nuclear pERK1/2 levels. Thus, assuming that reduction in nuclear pERK1/2 (Fig. 5C ) is a major effect of this drug, small changes in pERK1/2 detectable by Western blot could be associated with large changes in Ki67. Regarding other mechanisms of drug response, an increase in sub-G 0 (apoptotic) cells and cleaved caspase-3 activities were seen in treated cells in vitro, indicating that the apoptotic pathway is active with PD0325901 treatment. The level of apoptosis was, however, distinctly low in both tumor types, indicating that apoptosis was not a major mechanism of tumor growth inhibition. An important consideration for pharmacodynamic assessment of pathway-specific drugs is that the concentration of drug required to inhibit pathway activity may be insufficient to inhibit downstream signaling irrespective of upstream mutational status. The use of end points, such as [
18 F]FLT-PET, that report on growth inhibition should be considered alongside end points which report on target activity.
In summary, [ 18 F]FLT-PET is a sensitive imaging biomarker for detecting the antiproliferative effect of MEK1/2 inhibition by PD0325901; it does not directly measure MEK1/2 activity. This imaging method may be useful in the clinical development of PD0325901 and other inhibitors of the MAPK pathway.
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